91 filings
8-K
SNPX
Synaptogenix Inc
4 Apr 24
Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing
5:00pm
10-K
2023 FY
SNPX
Synaptogenix Inc
Annual report
1 Apr 24
5:00pm
8-K
SNPX
Synaptogenix Inc
21 Dec 23
Departure of Directors or Certain Officers
5:00pm
ARS
2022 FY
SNPX
Synaptogenix Inc
14 Nov 23
Annual report to shareholders
5:05pm
10-Q
2023 Q3
SNPX
Synaptogenix Inc
Quarterly report
14 Nov 23
5:00pm
8-K
wfgy3y2ywbb53a
6 Nov 23
Entry into a Material Definitive Agreement
5:00pm
8-K
npy0x 9kabyx7
22 Sep 23
Amendments to Articles of Incorporation or Bylaws
4:05pm
8-K
erqsci95 hsq3ypt
19 Jul 23
Study will evaluate drug’s potential neuro-restorative mechanism(s) of action for improving synaptic health and cognitive function in MS patients
8:55am
8-K
sehuqsy9ay27
22 Jun 23
Departure of Directors or Certain Officers
5:14pm
8-K
qry1r ym7alecw
28 Apr 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:00pm
8-K
0cfhnlvd fimf
14 Apr 23
Submission of Matters to a Vote of Security Holders
5:00pm
8-K
qcokjolmh
7 Mar 23
Results of Operations and Financial Condition
9:05am
8-K
pofqkva897e175d6c
17 Feb 23
Submission of Matters to a Vote of Security Holders
5:00pm